Oxford, UK – PrecisionLife’s unique AI platform has found 68 genes associated with risk of developing severe COVID-19 after analysis of the genomes of 929 patients from the UK Biobank who had a severe response to SARS-CoV-2.
OXFORD, UK: PrecisionLife featured as a case study of how a data-driven techbio company is transforming drug discovery and…15/10/21
The blockbuster model for drug discovery and development in chronic diseases is inefficient and costly. We need a new…12/10/21
Unique approach to precision medicine could reverse the trend in Alzheimer’s disease drug discovery and development Clinical trials in…27/09/21